These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

946 related articles for article (PubMed ID: 21524610)

  • 1. Oral Candida isolates among HIV-infected subjects in Nigeria.
    Nweze EI; Ogbonnaya UL
    J Microbiol Immunol Infect; 2011 Jun; 44(3):172-7. PubMed ID: 21524610
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro susceptibility of oral Candida to seven antifungal agents.
    Kuriyama T; Williams DW; Bagg J; Coulter WA; Ready D; Lewis MA
    Oral Microbiol Immunol; 2005 Dec; 20(6):349-53. PubMed ID: 16238594
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activity of voriconazole, itraconazole, fluconazole and amphotericin B in vitro against 1763 yeasts from 472 patients in the voriconazole phase III clinical studies.
    Johnson E; Espinel-Ingroff A; Szekely A; Hockey H; Troke P
    Int J Antimicrob Agents; 2008 Dec; 32(6):511-4. PubMed ID: 18790613
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Significance of isolation and drug susceptibility testing of non-Candida albicans species causing oropharyngeal candidiasis in HIV patients.
    Nadagir SD; Chunchanur SK; Halesh LH; Yasmeen K; Chandrasekhar MR; Patil BS
    Southeast Asian J Trop Med Public Health; 2008 May; 39(3):492-5. PubMed ID: 18564689
    [TBL] [Abstract][Full Text] [Related]  

  • 5. National surveillance of species distribution in blood isolates of Candida species in Japan and their susceptibility to six antifungal agents including voriconazole and micafungin.
    Takakura S; Fujihara N; Saito T; Kudo T; Iinuma Y; Ichiyama S
    J Antimicrob Chemother; 2004 Feb; 53(2):283-9. PubMed ID: 14688039
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Species distribution and antifungal susceptibility profile of oral candida isolates from HIV-infected patients in the antiretroviral therapy era.
    Costa CR; de Lemos JA; Passos XS; de Araújo CR; Cohen AJ; Souza LK; Silva Mdo R
    Mycopathologia; 2006 Jul; 162(1):45-50. PubMed ID: 16830191
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Species distribution, antifungal susceptibility and clonal relatedness of Candida isolates from patients in neonatal and pediatric intensive care units at a medical center in Turkey.
    Kuzucu C; Durmaz R; Otlu B; Aktas E; Gulcan H; Cizmeci Z
    New Microbiol; 2008 Jul; 31(3):401-8. PubMed ID: 18843896
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Candida spp. in vitro susceptibility profile to four antifungal agents. Resistance surveillance study in Venezuelan strains.
    Panizo MM; Reviákina V; Dolande M; Selgrad S
    Med Mycol; 2009 Mar; 47(2):137-43. PubMed ID: 18651308
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antifungal susceptibility of bloodstream yeasts isolated at a public children's hospital in Brazil: comparison of the Etest and the AFST-EUCAST microdilution method.
    Matsumoto FE; Dias AL; Melhem MS; Szeszs MW; Auler ME; Ruiz LS; Gonçalves da Silva E; Gandra RF; Paula CR
    Can J Microbiol; 2007 Dec; 53(12):1300-6. PubMed ID: 18059562
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dynamic analysis of oral Candida carriage, distribution, and antifungal susceptibility in HIV-infected patients during the first year of highly active antiretroviral therapy in Guangxi, China.
    Jiang L; Yong X; Li R; Peng Y; Liu W; Qin Q; Zhang L; Liu Z; Liang H; Tao R
    J Oral Pathol Med; 2014 Oct; 43(9):696-703. PubMed ID: 24931443
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Results from the ARTEMIS DISK Global Antifungal Surveillance study, 1997 to 2005: an 8.5-year analysis of susceptibilities of Candida species and other yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing.
    Pfaller MA; Diekema DJ; Gibbs DL; Newell VA; Meis JF; Gould IM; Fu W; Colombo AL; Rodriguez-Noriega E;
    J Clin Microbiol; 2007 Jun; 45(6):1735-45. PubMed ID: 17442797
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro susceptibility testing of Candida and Aspergillus spp. to voriconazole and other antifungal agents using Etest: results of a French multicentre study.
    Mallié M; Bastide JM; Blancard A; Bonnin A; Bretagne S; Cambon M; Chandenier J; Chauveau V; Couprie B; Datry A; Feuilhade M; Grillot R; Guiguen C; Lavarde V; Letscher V; Linas MD; Michel A; Morin O; Paugam A; Piens MA; Raberin H; Tissot E; Toubas D; Wade A
    Int J Antimicrob Agents; 2005 Apr; 25(4):321-8. PubMed ID: 15784312
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The evolution of Candida species and fluconazole susceptibility among oral and vaginal isolates recovered from human immunodeficiency virus (HIV)-seropositive and at-risk HIV-seronegative women.
    Sobel JD; Ohmit SE; Schuman P; Klein RS; Mayer K; Duerr A; Vazquez JA; Rampalo A;
    J Infect Dis; 2001 Jan; 183(2):286-93. PubMed ID: 11204125
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Isolation, characterization and antifungal susceptibility pattern of Candida species causing oropharyngeal candidiasis in HIV positive patients.
    Maninder J; Usha A
    J Commun Dis; 2008 Sep; 40(3):177-81. PubMed ID: 19245155
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Susceptibility of candida isolates from denture-related stomatitis to antifungal agents in vitro.
    Dorocka-Bobkowska B; Konopka K
    Int J Prosthodont; 2007; 20(5):504-6. PubMed ID: 17944341
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of Candida dubliniensis in oropharyngeal samples from human immunodeficiency virus-infected patients in North America by primary CHROMagar candida screening and susceptibility testing of isolates.
    Kirkpatrick WR; Revankar SG; Mcatee RK; Lopez-Ribot JL; Fothergill AW; McCarthy DI; Sanche SE; Cantu RA; Rinaldi MG; Patterson TF
    J Clin Microbiol; 1998 Oct; 36(10):3007-12. PubMed ID: 9738058
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection and antifungal susceptibility testing of oral Candida dubliniensis from human immunodeficiency virus-infected patients.
    Chunchanur SK; Nadgir SD; Halesh LH; Patil BS; Kausar Y; Chandrasekhar MR
    Indian J Pathol Microbiol; 2009; 52(4):501-4. PubMed ID: 19805956
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emergence of non-albicans Candida species and antifungal resistance in a tertiary care hospital.
    Capoor MR; Nair D; Deb M; Verma PK; Srivastava L; Aggarwal P
    Jpn J Infect Dis; 2005 Dec; 58(6):344-8. PubMed ID: 16377864
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the broth microdilution (BMD) method of the European Committee on Antimicrobial Susceptibility Testing and the Clinical Laboratory Standards Institute BMD method for non-Candida albicans and non-C. tropicalis bloodstream isolates from eleven tertiary hospitals in São Paulo state, Brazil.
    Purisco SU; Martins MA; Szeszs MW; Castro e Silva DM; Pukinskas SR; Bonfietti LX; Baez AA; Melhem MS
    FEMS Yeast Res; 2012 Dec; 12(8):890-6. PubMed ID: 22883021
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fluconazole resistant opportunistic oro-pharyngeal Candida and non-Candida yeast-like isolates from HIV infected patients attending ARV clinics in Lagos, Nigeria.
    Enwuru CA; Ogunledun A; Idika N; Enwuru NV; Ogbonna F; Aniedobe M; Adeiga A
    Afr Health Sci; 2008 Sep; 8(3):142-8. PubMed ID: 19357740
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 48.